bioshares calculated that royalty revenue from the sale of...

bioshares calculated that royalty revenue from the sale of evamist(menopausal spray) is currently about $500,000 per annum and growing almost in a straight line up.(currently supplying 2500 scrips per week/est sales 5.5 million per annum us)if they reach there estimated peak sales of 125 million us their revenue from this would be $24 million us. so you can see that as sales grow there is a very good ramp up with the royalty income.within the next 6 months ellavie(which is the name used for the menopausal spray other than usa)rights will be sold around the rest of the world.the revenue stream from evamist/ellavie could be very substantial.